3.5.4.4 (+)-erythro-9-(2-hydroxy-3-nonyl)adenine - 163510 3.5.4.4 (2S,3R)-3-(6-amino-9H-purin-9-yl)nonan-2-ol - 42126 3.5.4.4 (S)-(-)-epoxydecane - 132683 3.5.4.4 1,6-Dihydro-6-(hydroxymethyl)purine riboside - 90438 3.5.4.4 1-(4-benzylphenyl)-3-[4-[(4-oxo-4,5-dihydro-2H-pyrazolo[3,4-d]pyrimidin-2-yl)methyl]phenyl]urea - 74003 3.5.4.4 1-(4-fluorophenyl)-3-[4-[(4-oxo-4,5-dihydro-2H-pyrazolo[3,4-d]pyrimidin-2-yl)methyl]phenyl]urea - 74000 3.5.4.4 1-(4-methoxyphenyl)-3-[4-[(4-oxo-4,5-dihydro-2H-pyrazolo[3,4-d]pyrimidin-2-yl)methyl]phenyl]urea - 73999 3.5.4.4 1-(hydroxymethyl)nonyl methanesulfonate - 132682 3.5.4.4 1-(tert-butyldimethylsilanyloxy)-decan-2-ol - 132680 3.5.4.4 1-(tert-butyldimethylsilanyloxymethyl)nonyl methanesulfonate - 132681 3.5.4.4 1-alkyl-3-amino-4-pyrazolecarbonitriles - 132674 3.5.4.4 1-alkyl-4-aminopyrazolo[3,4d]pyrimidines - 132684 3.5.4.4 1-benzyl-3-[4-[(4-oxo-4,5-dihydro-2H-pyrazolo[3,4-d]pyrimidin-2-yl)methyl]phenyl]urea - 74005 3.5.4.4 1-deazaadenosine - 6846 3.5.4.4 1-methyl adenosine - 103801 3.5.4.4 1-[(1R)-1-(hydroxymethyl)-3-(6-[[(1-methyl-1H-benzimidazol-2-yl)acetyl]amino]-1H-indol-1-yl)propyl]-1H-imidazole-4-carboxamide - 73992 3.5.4.4 1-[(1R)-1-(hydroxymethyl)-3-naphthalen-1-ylpropyl]-1H-imidazole-4-carboxamide - 73988 3.5.4.4 1-[(1R)-1-(hydroxymethyl)-3-phenylpropyl]-1H-imidazole-4-carboxamide - 73987 3.5.4.4 1-[(1R)-2-hydroxy-1-phenylethyl]-1H-imidazole-4-carboxamide - 73986 3.5.4.4 1-[(1R)-3-[6-(acetylamino)-1H-indol-1-yl]-1-(hydroxymethyl)propyl]-1H-imidazole-4-carboxamide - 73990 3.5.4.4 1-[(1R)-3-[6-(hexanoylamino)-1H-indol-1-yl]-1-(hydroxymethyl)propyl]-1H-imidazole-4-carboxamide - 73991 3.5.4.4 1-[(1R,2S)-2-hydroxy-1-(2-naphthalen-1-ylethyl)propyl]-1H-imidazole-4-carboxamide - 73989 3.5.4.4 1-[(R)-1-hydroxy-4-(1-methyl-5-(3-phenylpropoxy)indol-3-yl)-2-butyl]imidazole-4-carboxamide - 60990 3.5.4.4 1-[(R)-1-hydroxy-4-(5-(3-phenylpropoxy)indol-1-yl)-2-butyl]imidazole-4-carboxamide - 60987 3.5.4.4 1-[(R)-1-hydroxy-4-(6-(3-(1-methylbenzimidazol-2-yl)propionylamino)indol-1-yl)-2-butyl]imidazole-4-carboxamide - 60971 3.5.4.4 1-[(R)-1-hydroxy-4-(6-(3-(3-pyridyl)propionylamino)indol-1-yl)-2-butyl]imidazole-4-carboxamide - 60980 3.5.4.4 1-[(R)-1-hydroxy-4-(6-(3-(4-methoxyphenyl)propionylamino)indol-1-yl)-1-hydroxy-2-butyl]imidazole-4-carboxamide - 60978 3.5.4.4 1-[(R)-1-hydroxy-4-(6-(3-(4-methylphenyl)propionylamino)indol-1-yl)-2-butyl]imidazole-4-carboxamide - 60977 3.5.4.4 1-[(R)-1-hydroxy-4-(6-(3-phenylpropionylamino)indol-1-yl)-2-butyl]imidazole-4-carboxamide - 60972 3.5.4.4 1-[(R)-1-hydroxy-4-(6-(3-phenylpropoxy)indol-1-yl)-2-butyl]imidazole-4-carboxamide - 60982 3.5.4.4 1-[(R)-1-hydroxy-4-(6-(4-(4-methylphenyl)butyrylamino)indol-1-yl)-2-butyl]imidazole-4-carboxamide - 60979 3.5.4.4 1-[(R)-1-hydroxy-4-(6-(4-phenylbutoxy)indol-1-yl)-2-butyl]imidazole-4-carboxamide - 60983 3.5.4.4 1-[(R)-1-hydroxy-4-(6-(4-phenylbutyrylamino)indol-1-yl)-2-butyl]imidazole-4-carboxamide - 60975 3.5.4.4 1-[(R)-1-hydroxy-4-(6-(5-phenylvalerylamino)indol-1-yl)-2-butyl]imidazole-4-carboxamide - 60970 3.5.4.4 1-[(R)-1-hydroxy-4-(6-(6-phenylhexanoylamino)indol-1-yl)-2-butyl]imidazole-4-carboxamide - 60976 3.5.4.4 1-[(R)-4-(5-(3-(4-chlorophenyl)propoxyl)-1-methylindol-3-yl)-1-hydroxy-2-butyl]imidazole-4-carboxamide - 60989 3.5.4.4 1-[(R)-4-(5-hexyloxy-1-methylindol-3-yl)-1-hydroxy-2-butyl]imidazole-4-carboxamide - 60991 3.5.4.4 1-[(R)-4-(5-hexyloxyindol-1-yl)-1-hydroxy-2-butyl]imidazole-4-carboxamide - 60988 3.5.4.4 1-[(R)-4-(6-(3-(4-chlorophenyl)propoxy)indol-1-yl)-1-hydroxy-2-butyl]imidazole-4-carboxamide - 60986 3.5.4.4 1-[(R)-4-(6-(3-benzylureido)indol-1-yl)-1-hydroxy-2-butyl]imidazole-4-carboxamide - 60981 3.5.4.4 1-[(R)-4-(6-acetylaminoindol-1-yl)-1-hydroxy-2-butyl]imidazole-4-carboxamide - 60973 3.5.4.4 1-[(R)-4-(6-butoxyindol-1-yl)-1-hydroxy-2-butyl]imidazole-4-carboxamide - 60985 3.5.4.4 1-[(R)-4-(6-hexanoylaminoindol-1-yl)-1-hydroxy-2-butyl]imidazole-4-carboxamide - 60974 3.5.4.4 1-[(R)-4-(6-hexyloxyindol-1-yl)-1-hydroxy-2-butyl]imidazole-4-carboxamide - 60984 3.5.4.4 1-[4-(dimethylamino)phenyl]-3-[4-[(4-oxo-4,5-dihydro-2H-pyrazolo[3,4-d]pyrimidin-2-yl)methyl]phenyl]urea - 74002 3.5.4.4 1-[4-[(4-oxo-4,5-dihydro-2H-pyrazolo[3,4-d]pyrimidin-2-yl)methyl]phenyl]-3-(4-phenoxyphenyl)urea - 74004 3.5.4.4 1-[4-[(4-oxo-4,5-dihydro-2H-pyrazolo[3,4-d]pyrimidin-2-yl)methyl]phenyl]-3-phenylurea - 73998 3.5.4.4 1-[4-[(4-oxo-4,5-dihydro-2H-pyrazolo[3,4-d]pyrimidin-2-yl)methyl]phenyl]-3-[4-(trifluoromethyl)phenyl]urea - 74001 3.5.4.4 2',3'-o-isopropyliden adenosine - 104380 3.5.4.4 2'-deoxy-4-amino-1-(beta-D-ribofuranosyl)-3H-imidazo[4,5-d]pyridazin-7-(6H)-one - 69263 3.5.4.4 2'-deoxy-7-amino-1-(beta-D-ribofuranosyl)-1H-imidazo[4,5-d]pyridazin-4-(5H)-one - 69264 3.5.4.4 2'-deoxycoformycin - 5090 3.5.4.4 2'-deoxyinosine - 2187 3.5.4.4 2,6-diaminopurine - 2634 3.5.4.4 2,6-diaminopurine sulfate - 103807 3.5.4.4 2-alkyl-4-aminopyrazolo[3,4d]pyrimidines - 132678 3.5.4.4 2-Amino-4-hydroxypteridine - 5093 3.5.4.4 2-Aminopurine - 6419 3.5.4.4 2-Deoxycoformycin - 43123 3.5.4.4 2-mercaptoethanol - 63 3.5.4.4 3-amino-1-(2-hydroxy-3-nonyl)4-pyrazolecarbonitrile - 132677 3.5.4.4 3-amino-1-(2-keto-3-nonyl)4-pyrazolecarbonitrile - 132676 3.5.4.4 3-amino-1-beta-hydroxyalkyl-4-pyrazolecarbonitriles - 132675 3.5.4.4 3-deazaadenosine - 2189 3.5.4.4 4-acetylamino-2-decylpyrazolo[3,4d]pyrimidine - 132679 3.5.4.4 4-amino-1-(2-hydroxy-3-nonyl)pyrazolo[3,4d]pyrimidine - 60968 3.5.4.4 4-amino-1-(beta-D-ribofuranosyl)-3H-imidazo[4,5-d]pyridazin-7-(6H)-one - 69265 3.5.4.4 4-amino-1-(beta-hydroxyethyl)pyrazolo[3,4d]pyrimidine - 60969 3.5.4.4 4-amino-1-(beta-hydroxyoctyl)pyrazolo[3,4d]pyrimidine - 132685 3.5.4.4 4-amino-2-decyl-6-phenylpyrazolo[3,4d]pyrimidine - 132686 3.5.4.4 4-amino-5-imidazole carboxamide-HCl - 103829 3.5.4.4 4-amino-5-imidazole carboxyamide ribonucleoside - 104960 3.5.4.4 4-fluoro-N-[4-[(4-oxo-4,5-dihydro-2H-pyrazolo[3,4-d]pyrimidin-2-yl)methyl]phenyl]benzamide - 73995 3.5.4.4 4-methoxy-N-[4-[(4-oxo-4,5-dihydro-2H-pyrazolo[3,4-d]pyrimidin-2-yl)methyl]phenyl]benzamide - 73994 3.5.4.4 5'-methylthio-2'-deoxycoformycin - 69269 3.5.4.4 5'-methylthiocoformycin - 5418 3.5.4.4 5-carbamimidoyl-1-(beta-D-ribofuranosyl)-1H-imidazole-4-carbohydrazide - 69267 3.5.4.4 6-Chloropurine - 2823 3.5.4.4 6-methylamino riboside - 48758 3.5.4.4 6-Methylmercaptopurine riboside - 5922 3.5.4.4 7,8-dihydro-1-p-methoxybenzyl-6H-6,7-dimethyl-8-propoxyimidazo[4,5-e][1,2,4]-triazepine - 56223 3.5.4.4 7,8-dihydro-1-p-methoxybenzyl-8-(2-methoxyethoxy)-6H-6,7-dimethylimidazo[4,5-e][1,2,4]triazepine - 56226 3.5.4.4 7,8-dihydro-1-p-methoxybenzyl-8-(3-methylbenzyloxy)-6H-6,7-dimethylimidazo[4,5-e][1,2,4]triazepine - 56228 3.5.4.4 7,8-dihydro-1-p-methoxybenzyl-8-(4-methoxybenzyloxy)-6H-6,7-dimethylimidazo[4,5-e][1,2,4]triazepine - 56227 3.5.4.4 7,8-dihydro-8-ethoxy-1-p-methoxybenzyl-6H-6,7-dimethylimidazo[4,5-e][1,2,4]triazepine - 56222 3.5.4.4 7,8-dihydro-8-isopropoxy-1-p-methoxybenzyl-6H-6,7-dimethylimidazo[4,5-e][1,2,4]triazepine - 56225 3.5.4.4 7,8-dihydro-8-methoxy-1-p-methoxybenzyl-6H-6,7-dimethylimidazo[4,5-e][1,2,4]triazepine - 56221 3.5.4.4 7-amino-1-(beta-D-ribofuranosyl)-1H-imidazo[4,5-d]pyridazin-4-(5H)-one - 69266 3.5.4.4 8-Bromoadenosine - 9087 3.5.4.4 8-butoxy-7,8-dihydro-1-p-methoxybenzyl-6H-6,7-dimethylimidazo[4,5-e][1,2,4]triazepine - 56224 3.5.4.4 9-(p-aminobenzyl)adenine - 105317 3.5.4.4 Acetylsalicylic acid - 2261 3.5.4.4 adenine - 144 3.5.4.4 adenosine analogs - 105369 3.5.4.4 adenosine monosulfate - 92294 3.5.4.4 Ag+ - 75 3.5.4.4 Ag2+ - 1041 3.5.4.4 aminoxyacetic acid - 92440 3.5.4.4 AMP - 30 3.5.4.4 ATP - 4 3.5.4.4 aza adenosine analogues - 105497 3.5.4.4 basic histone proteins - 105510 3.5.4.4 Caffeine - 882 3.5.4.4 Cd2+ - 52 3.5.4.4 Co2+ - 23 3.5.4.4 coformycin - 2648 3.5.4.4 cordycepin - 5954 3.5.4.4 corticosterone - 1103 3.5.4.4 Cu2+ - 19 3.5.4.4 deaza adenosine analogues - 105867 3.5.4.4 Deoxycoformycin - 5147 3.5.4.4 DEPC - 24059 3.5.4.4 diethyl dicarbonate - 463 3.5.4.4 EDTA - 21 3.5.4.4 erythro-9-(2-hydroxy-3-nonyl)-3-deazaadenine - 34635 3.5.4.4 erythro-9-(2-hydroxy-3-nonyl)-adenine - 11514 3.5.4.4 erythro-9-(2-hydroxy-3-nonyl)adenine - 2020 3.5.4.4 erythro-9-(2-hydroxy-3-nonyl)adenine hydrochloride - 69268 3.5.4.4 Fe2+ - 25 3.5.4.4 folic acid - 2840 3.5.4.4 guanosine - 296 3.5.4.4 heparin - 227 3.5.4.4 Hg2+ - 33 3.5.4.4 hypoxanthine - 211 3.5.4.4 Inosine - 167 3.5.4.4 iodoacetamide - 67 3.5.4.4 iodoacetic acid - 213 3.5.4.4 Iodopurine - 93713 3.5.4.4 K+ - 39 3.5.4.4 L-cysteine - 74 3.5.4.4 lysozyme - 3115 3.5.4.4 Mg2+ - 6 3.5.4.4 Mn2+ - 11 3.5.4.4 N-ethylmaleimide - 49 3.5.4.4 N-[4-[(4-oxo-4,5-dihydro-2H-pyrazolo[3,4-d]pyrimidin-2-yl)methyl]phenyl]-2-phenylacetamide - 73997 3.5.4.4 N-[4-[(4-oxo-4,5-dihydro-2H-pyrazolo[3,4-d]pyrimidin-2-yl)methyl]phenyl]-4-(trifluoromethyl)benzamide - 73996 3.5.4.4 N-[4-[(4-oxo-4,5-dihydro-2H-pyrazolo[3,4-d]pyrimidin-2-yl)methyl]phenyl]benzamide - 73993 3.5.4.4 N6-methyladenosine - 6566 3.5.4.4 Na+ - 59 3.5.4.4 NH4+ - 54 3.5.4.4 Ni2+ - 38 3.5.4.4 o-phenanthroline - 239 3.5.4.4 p-chloromercuribenzoate - 43 3.5.4.4 p-chloromercuryphenylsulfonate - 106956 3.5.4.4 p-hydroxymercuribenzoic acid - 4631 3.5.4.4 Pb2+ - 139 3.5.4.4 Pentachlorophenol - 1077 3.5.4.4 pentostatin - 35853 3.5.4.4 purine riboside - 2984 3.5.4.4 reduced glutathione - 593 3.5.4.4 spermidine - 148 3.5.4.4 Theobromine - 2761 3.5.4.4 theophylline - 1221 3.5.4.4 thiol reagents - 3246 3.5.4.4 Urea - 116 3.5.4.4 Zn2+ - 14 3.5.4.4 2'-deoxycoformycin 0.0004 nM, 50% inhibition 5090 3.5.4.4 2'-deoxycoformycin 0.0015 nM, 50% inhibition 5090 3.5.4.4 Cu2+ 0.029 mM, 50% inhibition 19 3.5.4.4 Mn2+ 0.046 mM, 50% inhibition 11 3.5.4.4 Mg2+ 0.055 mM, 50% inhibition 6 3.5.4.4 erythro-9-(2-hydroxy-3-nonyl)-adenine 0.1 mM concentration, ADA2 is practically unaffected; 0.1 mM concentration, complete and reversible inhibition 11514 3.5.4.4 2'-deoxycoformycin 0.15 nM, 50% inhibition 5090 3.5.4.4 erythro-9-(2-hydroxy-3-nonyl)-adenine hydrochloride 0.4 nM, 50% inhibition 23131 3.5.4.4 erythro-9-(2-hydroxy-3-nonyl)-adenine hydrochloride 0.45 nM, 50% inhibition 23131 3.5.4.4 7-chloro-5-methyl-3-(beta-D-ribofuranosyl)-3H-imidazo[4,5-b]pyridin-6-amine 15% inhibition at 0.4 mM 206631 3.5.4.4 5-methyl-3-(2,3,5-tri-O-acetyl-beta-D-ribofuranosyl)-3H-imidazo[4,5-b]pyridin-6-amine 19% inhibition at 0.4 mM 206625 3.5.4.4 2,2,2-trifluoro-N-[7-chloro-5-methyl-3-(2,3,5-tri-O-acetyl-beta-D-ribofuranosyl)-3H-imidazo[4,5-b]pyridin-6-yl]-acetamide 20% inhibition at 0.4 mM 206629 3.5.4.4 2,2,2-trifluoro-N-[7-chloro-5-methyl-3-(beta-D-ribofuranosyl)-3H-imidazo[4,5-b]pyridin-6-yl]acetamide 23% inhibition at 0.4 mM 206630 3.5.4.4 5-(beta-D-ribofuranosyl)-1H,5H-imidazo[4,5-b]pyrazolo[3,4-e]pyridine 25% inhibition at 0.4 mM 206627 3.5.4.4 5-methyl-6-nitro-3-(beta-D-ribofuranosyl)-3H-imidazo[4,5-b]pyridine 25% inhibition at 0.4 mM 206624 3.5.4.4 1-[(2S,3R)-2,3-dihydroxycyclopentyl]-5-(1,3-thiazol-5-yl)pyrimidine-2,4(1H,3H)-dione 28% inhibition at 0.1 mM 204831 3.5.4.4 Inosine 31% inhibition at 0.1 mM 167 3.5.4.4 5-methyl-6-nitro-3-(2,3,5-tri-O-acetyl-beta-D-ribofuranosyl)-3H-imidazo[4,5-b]pyridine 31% inhibition at 0.4 mM 206623 3.5.4.4 1-[(2S,3R)-2,3-dihydroxycyclopentyl]-5-(furan-2-yl)pyrimidine-2,4(1H,3H)-dione 35% inhibition at 0.1 mM 204832 3.5.4.4 1-[(2S,3R)-2,3-dihydroxycyclopentyl]-5-(thiophen-2-yl)pyrimidine-2,4(1H,3H)-dione 36% inhibition at 0.1 mM 204833 3.5.4.4 Ba2+ 44% inhibition at 5 mM 111 3.5.4.4 1-[(4R,5S)-4,5-dihydroxycyclopent-2-en-1-yl]-5-(thiophen-2-yl)pyrimidine-2,4(1H,3H)-dione 48% inhibition at 0.1 mM 204847 3.5.4.4 1-[(4R,5S)-4,5-dihydroxycyclopent-2-en-1-yl]-5-(1,3-thiazol-5-yl)pyrimidine-2,4(1H,3H)-dione 49% inhibition at 0.1 mM 204845 3.5.4.4 2'-deoxyformycin 50% inhibition of isozyme ADA2 at 0.09 mM 132687 3.5.4.4 1-[(4R,5S)-4,5-dihydroxycyclopent-2-en-1-yl]-5-(furan-2-yl)pyrimidine-2,4(1H,3H)-dione 55% inhibition at 0.1 mM 204846 3.5.4.4 5-methyl-3-(beta-D-ribofuranosyl)-3H-imidazo[4,5-b]pyridin-6-amine 6% inhibition at 0.4 mM 206626 3.5.4.4 Ni2+ 61% inhibition at 5 mM 38 3.5.4.4 Zn2+ 65% inhibition at 5 mM 14 3.5.4.4 Ca2+ 69% inhibition at 5 mM 15 3.5.4.4 7-(beta-D-ribofuranosyl)-1H,7H-imidazo[4,5-b]pyrazolo[3,4-e]pyridine 7% inhibition at 0.4 mM 206628 3.5.4.4 Cu2+ 81% inhibition at 5 mM 19 3.5.4.4 Mn2+ 85% inhibition at 5 mM 11 3.5.4.4 Hg2+ 88% inhibition at 5 mM 33 3.5.4.4 2'-deoxycoformycin a natural product transition state analogue inhibitor 5090 3.5.4.4 coformycin a natural product transition state analogue inhibitor 2648 3.5.4.4 erythro-9-(2-hydroxy-3-nonyl)adenine ADA-specific inhibitor, almost complete inhibition at 0.00005 mM 2020 3.5.4.4 additional information ADA1 activity is not changed significantly by aspirin, metoprolol, isosorbide mononitrate, and molsidominemolsidomine; molsidomine does not influence plasma adenosine deaminase activity significantly 2 3.5.4.4 6-fluoro-D,L-tryptophan adenosine analogue, induces conformational changes inhibiting the enzyme, structural mechanism, overview 132672 3.5.4.4 purine riboside adenosine analogue, induces conformational changes inhibiting the enzyme, structural mechanism, overview 2984 3.5.4.4 IgG anti adenosine deaminase 20955 3.5.4.4 Sodium dodecyl sulfate at low concentrations (approximately 0.1 mM) enzyme activity decreases, it increases at a slightly higher concentration (about 0.4 mM), and finally decreases again (about 0.55 mM), CD spectra of adenosine deaminase and SDS, determination of helix content, MD calculations 1358 3.5.4.4 dodecyltrimethylammonium bromide at low concentrations (approximately 0.1 mM), enzyme activity decreases, it increases at a slightly higher concentration (about 0.2 mM), and finally decreases again (about 0.3 mM), CD spectra of adenosine deaminase and DTAB, determination of helix content, MD calculations 8444 3.5.4.4 ethanol CD spectra of adenosine deaminase and EtOH, determination of helix content, MD calculations 69 3.5.4.4 Na2SO4 CD spectra of adenosine deaminase and Na2SO4, determination of helix content, MD calculations, discussion of effects 733 3.5.4.4 (2S,3R)-3-(6-amino-9H-purin-9-yl)-5-[3-(trifluoromethyl)phenyl]pentan-2-ol comopound shows suitable balance of potency, microsomal stability and demonstrates better pharmacokinetic properties as compared to (+)-erythro-9-(2-hydroxy-3-nonyl)adenine 237480 3.5.4.4 (2S,3R)-3-(6-amino-9H-purin-9-yl)-5-[4-(trifluoromethyl)phenyl]pentan-2-ol comopound shows suitable balance of potency, microsomal stability and demonstrates better pharmacokinetic properties as compared to (+)-erythro-9-(2-hydroxy-3-nonyl)adenine 237481 3.5.4.4 1-[(3R,4S)-4-hydroxy-1-[3-(trifluoromethyl)phenyl]pentan-3-yl]-1H-imidazole-4-carboxamide comopound shows suitable balance of potency, microsomal stability and demonstrates better pharmacokinetic properties as compared to (+)-erythro-9-(2-hydroxy-3-nonyl)adenine 237482 3.5.4.4 acetaminophen competitive at 27°C, uncompetitive at 37°C 2541 3.5.4.4 diclofenac competitive at 27°C, uncompetitive at 37°C 1291 3.5.4.4 2-Aminopurine competitive inhibition 6419 3.5.4.4 4-aminopyridine competitive inhibition 13387 3.5.4.4 4-aminopyrimidine competitive inhibition 69271 3.5.4.4 4-hydroxypyridine competitive inhibition 10837 3.5.4.4 adenine competitive inhibition 144 3.5.4.4 Inosine competitive inhibition 167 3.5.4.4 phenylhydrazine competitive inhibition 398 3.5.4.4 purine competitive inhibition 2218 3.5.4.4 coformycin complete inhibition of ADA2 at 1 mM 2648 3.5.4.4 methylmercury concentration 0.1, 1.0, 20 M, inhibits adenosine deaminase activity in 7- and 60-day-old rats in a concentration-dependent manner, glutathione (50 microM) and dithiothreitol (50 microM) prevent the reduction of adenosine deaminase activity both in cerebral cortex and hippocampus, garlic alcoholic extract (100 microg/ml) abolishes the reduction of adenosine deaminase 10229 3.5.4.4 additional information cytotoxic effects of inhibitors against human breast cancer cell lines MCF-7 and MCF-10A 2 3.5.4.4 Zn2+ decrease of 31.3% on adenosine deamination in membranes is observed in the presence of 5 mM Zn2+ 14 3.5.4.4 Sodium selenate does not alter enzyme activity 30410 3.5.4.4 erythro-9-(2-hydroxy-3-nonyl)adenine EHNA 0.1mM 2020 3.5.4.4 erythro-9-(2-hydroxy-3-nonyl)adenine i.e. (+)-EHNA 2020 3.5.4.4 pentostatin i.e. (8R)-3-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydro-2-furanyl]-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol 35853 3.5.4.4 FR234938 i.e. 1-((1R,2S)-2-hydroxy-1-(2-(1-naphthyl)ethyl)propyl)1H-imidazole-4-carboxamine, a non-nucleoside inhibitor, the inhibition is blocked by an A2a adenosine receptor antagonist 69270 3.5.4.4 1-deaza-erythro-9-(2-hydroxy-3-nonyl)adenine i.e. 1-dEHNA 11669 3.5.4.4 pentostatin i.e. 2'-deoxycoformycin, a selective ADA inhibitor 35853 3.5.4.4 3-deaza-erythro-9-(2-hydroxy-3-nonyl)adenine i.e. 3-dEHNA 11670 3.5.4.4 nebularine i.e. 9-beta-D-ribofuranosylpurine, competitive inhibitor 15884 3.5.4.4 4-amino-2-(2-hydroxy-1-decyl)pyrazole[3,4-d]pyrimidine i.e. APP 144059 3.5.4.4 erythro-9-(2-hydroxy-3-nonyl)adenine i.e. EHNA 2020 3.5.4.4 erythro-9-(2-hydroxy-3-nonyl)adenine hydrochloride i.e. EHNA 69268 3.5.4.4 erythro-9-(2-hydroxy-3-nonyl)adenine i.e. EHNA, specific for isozyme ADA1 2020 3.5.4.4 erythro-9-(2-hydroxy-3-nonyl)adenine i.e. EHNA, specific for isozyme ADA1, no inhibition of isozyme ADA2 2020 3.5.4.4 adenosine analogues induce conformational changes inhibiting the enzyme, structural mechanism, overview 132673 3.5.4.4 HgCl2 inhibition of ADA activity is observed in the soluble fraction at 0.005-0.25 mM HgCl2 (84.6-92.6% respectively), whereas inhibition occurs at 0.005-0.25 mM in membrane fractions (20.9-26% respectively). The inhibition is partially or fully abolished by 0.5 mM dithiothreitol or EDTA 110 3.5.4.4 simvastatin inhibits ADA1 activity by 46.7%; significantly decreases adenosine deaminase activity, the half-life of adenosine will be lengthened as a consequence of decreased ADA activity 2311 3.5.4.4 corticosterone inhibits the adenosine deaminase activity in an age- and region-specific manner 1103 3.5.4.4 additional information loss of activity precedes the global secondary and tertiary structure transition when the enzyme is exposed to denaturant, structural mechanism, overview 2 3.5.4.4 methanol MD calculations, discussion of effects 83 3.5.4.4 NaCl MD calculations, discussion of effects 42 3.5.4.4 additional information molecular dynamic simulations of inhibitor-enzyme interaction, overview 2 3.5.4.4 epigallocatechin gallate most abundant and biologically active ?avonoid present in green tea, strong competitive inhibitory activity 1234 3.5.4.4 additional information no inhibition by erythro-9-(2-hydroxy-3-nonyl)-adenine hydrochloride 2 3.5.4.4 additional information no inhibition of the bovine enzyme by 5'-methylthiocoformycin and 5'-methylthio-2'-deoxycoformycin 2 3.5.4.4 additional information no inhibition of the human enzyme by 5'-methylthiocoformycin and 5'-methylthio-2'-deoxycoformycin 2 3.5.4.4 5'-methylthiocoformycin poor inhibitor of Plasmodium gallinaceum ADA 5418 3.5.4.4 coformycin powerful picomolar inhibitor of ADA 2648 3.5.4.4 D-coformycin powerful picomolar inhibitor of ADA 5440 3.5.4.4 progesterone progesterone decreases adenosine deaminase levels, adenosine deaminase levels show regional specificity with differences among the cerebral hemispheres, cerebellum, and brainstems structures 286 3.5.4.4 caffeic acid phenethyl ester reduces the enzyme activity in vivo, suppresses the induction of the enzyme by cisplatin in vivo 11671 3.5.4.4 aspirin significantly decreases adenosine deaminase activity, the half-life of adenosine will be lengthened as a consequence of decreased adenosine deaminase activity 3100 3.5.4.4 isosorbide mononitrate significantly decreases adenosine deaminase activity, the half-life of adenosine will be lengthened as a consequence of decreased adenosine deaminase activity 151881 3.5.4.4 metoprolol significantly decreases adenosine deaminase activity, the half-life of adenosine will be lengthened as a consequence of decreased adenosine deaminase activity 151880 3.5.4.4 (+)-erythro-9-(2-hydroxy-3-nonyl)adenine specific inhibitor of ADA1 163510 3.5.4.4 5'-methylthiocoformycin specific transition state analogue inhibitor of Plasmodium ADA 5418 3.5.4.4 5'-methylthiocoformycin specific transition state analogue inhibitor of Plasmodium ADA, 5'-methylthiocoformycin is a subnanomolar inhibitor of Plasmodium falciparum ADA and demonstrates more than 20000fold selectivity relative to human ADA 5418 3.5.4.4 Ca2+ strong inhibition 15 3.5.4.4 Mg2+ strong inhibition 6 3.5.4.4 additional information strong inhibition by the traditional Chinese medicines Rhizoma Chuanxiong and Angelica sinensis 2 3.5.4.4 additional information structure-based design, synthesis, and structure-activity relationship studies of non-nucleoside adenosine deaminase inhibitors, overview 2 3.5.4.4 indole-3-acetic acid the plant hormone decreases enzyme activity in hearts, but not in kidney and muscle 2965 3.5.4.4 kinetin the plant hormone decreases enzyme activity in hearts, but not in kidney and muscle 3475 3.5.4.4 additional information the trend of relative activity is directly proportional to helicity and inversely proportional to accessible surface area 2